NASDAQ:ADAP
Adaptimmune Therapeutics plc Stock News
$1.08
-0.0600 (-5.26%)
At Close: Apr 24, 2024
Why Shares of Adaptimmune Therapeutics Jumped Tuesday
12:13pm, Tuesday, 11'th Apr 2023
GSK gave Adaptimmune nearly $37 million as part of a rights deal. Adaptimmune said it expects to launch its first marketed therapy, possibly as soon as the end of this year.
Adaptimmune: TCR2 Merger Represents Opportunity For Enthusiastic Investors
07:12am, Sunday, 26'th Mar 2023
ADAP is down after merging with TCRR, while TCRR is up. The merger dilutes ADAP, but in return, it gets one year of additional cash and the TCRR pipeline for free.
Adaptimmune Therapeutics And TCR² Therapeutics To Merge (ADAP) (TCRR)
07:45am, Monday, 06'th Mar 2023
Adaptimmune Therapeutics plc (NASDAQ: ADAP) and TCR² Therapeutics Inc. (NASDAQ: TCRR) announced a plan to merge. These are the details.
Adaptimmune to Report Q4 and Full Year 2022 Financial and Business Updates on Monday, March 6, 2023
08:00am, Wednesday, 22'nd Feb 2023
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - February 22, 2023) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report fi
Adaptimmune: The Afamicel Rolling BLA Is Its Lifeline
03:24pm, Friday, 09'th Dec 2022
ADAP has been in a sea of trouble, lately. Its rolling BLA of afamicel, to be started this quarter, is its immediate lifeline.
5 Penny Stocks To Buy According To Analysts, Targets Up To 353%
10:38am, Friday, 11'th Nov 2022
Analysts say these are penny stocks to buy. Do you agree?
Why Adaptimmune Therapeutics Stock Is Glowing Green Today
03:11pm, Tuesday, 08'th Nov 2022
Positive trial data is powering the biotech's stock higher today.
Adaptimmune Therapeutics plc (ADAP) Q3 2022 Earnings Call Transcript
01:09pm, Tuesday, 08'th Nov 2022
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q3 2022 Earnings Conference Call November 8, 2022 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive O
Adaptimmune to Report Q3 2022 Financial and Business Updates on Tuesday, November 8, 2022
12:27pm, Thursday, 27'th Oct 2022
Philadelphia, Pennsylvania and Oxfordshire, United Kingdom--(Newsfile Corp. - October 27, 2022) - Adaptimmune Therapeutics plc (NASDAQ: ADAP), a leader in cell therapy to treat cancer, will report fin
Adaptimmune Therapeutics plc (ADAP) CEO Adrian Rawcliffe on Q2 2022 Results - Earnings Call Transcript
11:39pm, Saturday, 06'th Aug 2022
Adaptimmune Therapeutics plc (NASDAQ:ADAP ) Q2 2022 Earnings Conference Call August 4, 2022 8:00 AM ET Company Participants Juli Miller - Head-Investor Relations Adrian Rawcliffe - Chief Executive Off
Got $500? 3 Absurdly Cheap Healthcare Stocks That Are Set to Skyrocket
04:45pm, Friday, 01'st Jul 2022
Here's why these Fool.com contributors are bullish on Adaptimmune Therapeutics, G1 Therapeutics, and Axsome Therapeutics.
Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
05:59am, Wednesday, 29'th Jun 2022
SPEARHEAD-1 trial using afami-cel for the treatment of patients with synovial sarcoma and MRCLS met its primary endpoint with an objective response rate of 34%. A BLA filing for afami-cel for the trea
Why Adaptimmune Therapeutics Stock Is Popping Today
03:27pm, Monday, 27'th Jun 2022
Buyout fever is sparking interest in the biotech's beaten-down shares today.
Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
06:35am, Sunday, 19'th Jun 2022
Adaptimmune Therapeutics is a cell therapy company using their TCR-engineered T cells to take on various tumor types. Their leading program is MAGE-A4 which contains afami-cel, a TCR-engineered T cell
Why Shares of Adaptimmune Therapeutics Rose 13.4% on Tuesday
05:03pm, Tuesday, 17'th May 2022
The clinical-stage biotech saw its shares rise after releasing preclinical data on two of its therapies.
